GENERATION BIO CO (GBIO) Stock News
NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD
GBIO Latest News, Press Relases and Analysis
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio (GBIO) delivered earnings and revenue surprises of 12% and 464.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CTKB
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generation Bio (NASDAQ:GBIO) just reported results for the second quarter of 20...
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for...
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generation Bio (NASDAQ:GBIO) just reported results for the first quarter of 202...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - ...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for...
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing...
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass.,...
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q2 2024
GBIO stock results show that Generation Bio missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Generation Bio Reports Second Quarter 2024 Financial Results
Cash balance of $217 million still expected to fund operations into 2H 2027
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q1 2024
GBIO stock results show that Generation Bio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle...
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid...